H. Lundbeck A/S Commences Tender Offer For All Outstanding Shares Of Chelsea Therapeutics, Inc.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Valby, Denmark, 23 May 2014 - H. Lundbeck A/S (Lundbeck) today announced that it has commenced a tender offer to purchase all outstanding shares of Chelsea Therapeutics International, Ltd. (NYSE: CHTP) (Chelsea) for USD 6.44 per share in cash and CVRs that may pay up to an additional USD 1.50 per share upon achievement of certain sales milestones. The tender offer is being made by Charlie Acquisition Corp, a wholly-owned indirect subsidiary of Lundbeck, pursuant to the previously announced merger agreement between the companies.

Help employers find you! Check out all the jobs and post your resume.

Back to news